Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment

被引：0
|
作者：
Yazici, Yusuf [1 ]
McAlindon, Timothy E. [2 ]
Gibofsky, Allan [3 ,4 ]
Lane, Nancy E. [5 ]
Skrepnik, Nebojsa [6 ]
Armas, Eddie [7 ]
Swearingen, Christopher J. [1 ]
DiFrancesco, Anita [1 ]
Tambiah, Jeymi [1 ]
Hochberg, Marc [8 ,9 ]
机构：
[1] Samumed LLC, San Diego, CA USA
[2] Tufts Med Ctr, Div Rheumatol, Boston, MA USA
[3] Weill Cornell Med, Rheumatol, New York, NY USA
[4] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA
[5] Univ Calif Davis, Sch Med, Ctr Musculoskeletal Hlth, Sacramento, CA 95817 USA
[6] Tuscon Orthoped Inst, Tucson, AZ USA
[7] Well Pharma Med Res, Miami, FL USA
[8] Univ Maryland, Sch Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA
[9] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1204
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PROSPECTIVE COMPARISON OF INTRA-ARTICULAR SHAM VS. PLACEBO INJECTIONS: DATA FROM A RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SM04690, A WNT PATHWAY INHIBITOR FOR KNEE OSTEOARTHRITIS
    Yazici, Y.
    Tambiah, J.
    Swearingen, C.
    Kennedy, S.
    Strand, V.
    Cole, B.
    Hochberg, M.
    Bannuru, R.
    McAlindon, T.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S519 - S520
  • [42] Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
    Kennedy, Sarah
    Swearingen, Chris
    Tambiah, Jeyanesh
    Clauw, Daniel
    Conaghan, Philip G.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [43] Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study
    Yazici, Yusuf
    Majumdar, Sharmila
    McAlindon, Timothy E.
    Fleischmann, Roy
    Gibofsky, Allan
    Hochberg, Marc C.
    Swearingen, Christopher J.
    DiFrancesco, Anita
    Tambiah, Jeyanesh R. S.
    Hood, John
    Lane, Nancy E.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [44] HIGHER PAIN VARIATION DURING THE SCREENING PHASE IS ASSOCIATED WITH A LARGER PLACEBO RESPONSE - POST-HOC ANALYSIS OF A PHASE 2B KNEE OSTEOARTHRITIS TRIAL
    Bentin, Jakob M.
    Miller, Claire Prener
    Mondragon, Alejandro Castillo
    Adrian, Ida Sofie
    Arendt-Nielsen, Lars
    Alexandersen, Peter
    Bihlet, Asger R.
    OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S37 - S38
  • [45] LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK2/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, PROVIDED CARTILAGE-PROTECTIVE EFFECTS IN AN ANIMAL MODEL OF POST-TRAUMATIC OA
    Seo, T.
    Deshmukh, V.
    Yazici, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 60 - 60
  • [46] TREATMENT WITH LORECIVIVINT, A NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, LED TO IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS OF A PHASE 2B TRIAL
    Yazici, Y.
    Kennedy, S.
    Swearingen, C. J.
    Tambiah, J.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 : S358 - S358
  • [47] USING PAIN TOLERABILITY THRESHOLDS TO CHARACTERIZE CLINICALLY MEANINGFUL TREATMENT OUTCOMES IN KNEE OSTEOARTHRITIS: POST HOC ANALYSIS OF A PHASE 2B TRIAL OF INTRA-ARTICULAR LORECIVIVINT
    Markman, J. D.
    Bennett, H.
    Kennedy, S.
    Tambiah, J. R.
    Swearingen, C. J.
    Gewandter, J. S.
    OSTEOARTHRITIS AND CARTILAGE, 2022, 30 : S378 - S379
  • [48] Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study
    Guermazi, Ali
    Kraines, Jeffrey
    Aydemir, Aida
    Wax, Stephen
    Crema, Michel
    Hochberg, Marc C.
    Roemer, Frank
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [49] Unbiased analysis of knee cartilage thickness change over three years after sprifermin vs. placebo treatment - A post-hoc analysis from the phase 2B FORWARD study
    Eckstein, Felix
    Maschek, Susanne
    Wirth, Wolfgang
    Ladel, Christoph
    Bihlet, Asger Reinstrup
    Knight, Chris
    Somberg, Kenneth
    Zhao, Luping
    OSTEOARTHRITIS AND CARTILAGE OPEN, 2024, 6 (04):
  • [50] Effects of Tezepelumab on Asthma Exacerbations and Type 2 Biomarkers in Patients with Severe, Uncontrolled Asthma with and Without Nasal Polyps: Results from a Post-Hoc Analysis of the Phase 2b PATHWAY Study
    Emson, C.
    Corren, J.
    Saapa, K.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345